CONTINUATION OF TYROSINE KINASE INHIBITORS AFTER CHEMOTHERAPY IN PH plus ACUTE LYMPHOBLASTIC LEUKEMIA

被引：0
|
作者：
Smith, Stephanie [1 ]
Aftandilian, Catherine [1 ]
机构：
[1] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
010
引用
收藏
页数：2
相关论文
共 50 条
  • [41] MULTI-TARGETED TYROSINE KINASE INHIBITORS PLUS CHEMOTHERAPY
    Ivy, S. P.
    Chen, H.
    ANNALS OF ONCOLOGY, 2009, 20 : 25 - 25
  • [42] The overexpression of spliced oncogenic Ikaros isoforms in Philadelphia-positive (Ph plus) acute lymphoblastic leukemia (ALL) patients is a new mechanism of resistance to tyrosine kinase inhibitors.
    Iacobucci, I.
    Lonelti, A.
    Ottaviani, E.
    Cilloni, D.
    Messa, F.
    Paolini, S.
    Papayannidis, C.
    Panagiota, G.
    Soverini, S.
    Amabile, M.
    Poerio, A.
    Rondoni, M.
    Saglio, G.
    Pane, F.
    Berton, G.
    Baruzzi, A.
    Vitale, A.
    Foa, R.
    Baccarani, M.
    Martinelli, Giovanni
    BLOOD, 2007, 110 (11) : 221A - 222A
  • [43] Autologous HSCT for Ph-Positive Adult Acute Lymphoblastic Leukemia: A Curative Option in the Era of Tyrosine Kinase Inhibitors? an Analysis From the Acute Leukemia Working Party of the EBMT
    Giebel, Sebastian
    Labopin, Myriam
    Gorin, Norbert Claude
    Caillot, Denis
    Leguay, Thibaut
    Schaap, Nicolaas
    Michallet, Mauricette
    Socie, Gerard
    Mohty, Mohamad
    BLOOD, 2012, 120 (21)
  • [44] Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors
    Abou Dalle, Iman
    Kantarjian, Hagop M.
    Short, Nicholas J.
    Konopleva, Marina
    Jain, Nitin
    Garcia-Manero, Guillermo
    Garris, Rebecca
    Qiao, Wei
    Cortes, Jorge E.
    O'Brien, Susan
    Kebriaei, Partow
    Kadia, Tapan
    Jabbour, Elias
    Ravandi, Farhad
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) : 1388 - 1395
  • [45] THE FIRST AND SECOND GENERATION TYROSINE KINASE INHIBITORS ROLE IN THE PHILADELPHIA POSITIVE CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
    Koc, Basak
    Zulfikar, Bulent
    PEDIATRIC BLOOD & CANCER, 2015, 62 : 84 - 84
  • [46] Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors
    Ma, Yingying
    Zhang, Quanchao
    Kong, Peiyan
    Xiong, Jingkang
    Zhang, Xi
    Zhang, Cheng
    CHEMOTHERAPY, 2019, 64 (02) : 81 - 93
  • [47] PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: IS CHEMOTHERAPY NECESSARY?
    Foa, Robin
    LEUKEMIA RESEARCH, 2017, 61 : S4 - S5
  • [48] Survival Impact of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive (Ph plus ) de novo Acute Myeloid Leukemia (AML)
    Chan, Onyee
    Yun, Seongseok
    Halpern, Anna
    Babiker, Hani
    Sundararajan, Srinath
    Ramos, Jorge
    Hendrie, Paul
    Acharya, Utkarsh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S296 - S297
  • [49] Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Wang, Jing
    Jiang, Qian
    Xu, Lan-ping
    Zhang, Xiao-hui
    Chen, Huan
    Qin, Ya-zhen
    Ruan, Guo-rui
    Jiang, Hao
    Jia, Jin-song
    Zhao, Ting
    Liu, Kai-Yan
    Jiang, Bin
    Huang, Xiao-Jun
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (04) : 741 - 750
  • [50] Acute Pancreatitis in Children With Acute Lymphoblastic Leukemia After Chemotherapy
    Treepongkaruna, Suporn
    Thongpak, Naporn
    Pakakasama, Samart
    Pienvichit, Paneeya
    Sirachainan, Nongnuch
    Hongeng, Suradej
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2009, 31 (11) : 812 - 815
12345